BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cotugno N, Ruggiero A, Santilli V, Manno EC, Rocca S, Zicari S, Amodio D, Colucci M, Rossi P, Levy O, Martinon-Torres F, Pollard AJ, Palma P. OMIC Technologies and Vaccine Development: From the Identification of Vulnerable Individuals to the Formulation of Invulnerable Vaccines. J Immunol Res 2019;2019:8732191. [PMID: 31183393 DOI: 10.1155/2019/8732191] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Cotugno N, Santilli V, Pascucci GR, Manno EC, De Armas L, Pallikkuth S, Deodati A, Amodio D, Zangari P, Zicari S, Ruggiero A, Fortin M, Bromley C, Pahwa R, Rossi P, Pahwa S, Palma P. Artificial Intelligence Applied to in vitro Gene Expression Testing (IVIGET) to Predict Trivalent Inactivated Influenza Vaccine Immunogenicity in HIV Infected Children. Front Immunol 2020;11:559590. [PMID: 33123133 DOI: 10.3389/fimmu.2020.559590] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
2 Matsuoka S, Kuwata T, Ishii H, Sekizuka T, Kuroda M, Sano M, Okazaki M, Yamamoto H, Shimizu M, Matsushita S, Seki Y, Saito A, Sakawaki H, Hirsch VM, Miura T, Akari H, Matano T. A Potent anti-Simian Immunodeficiency Virus Neutralizing Antibody Induction Associated with a Germline Immunoglobulin Gene Polymorphism in Rhesus Macaques. J Virol 2021:JVI. [PMID: 33441342 DOI: 10.1128/JVI.02455-20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Amodio D, Santilli V, Zangari P, Cotugno N, Manno EC, Rocca S, Rossi P, Cancrini C, Finocchi A, Chassiakos A, Petrovas C, Palma P. How to dissect the plasticity of antigen-specific immune response: a tissue perspective. Clin Exp Immunol 2020;199:119-30. [PMID: 31626717 DOI: 10.1111/cei.13386] [Reference Citation Analysis]
4 Nomura Y, Matsuoka S, Okazaki M, Kuwata T, Matano T, Ishii H. Neutralizing Antibody Induction Associated with a Germline Immunoglobulin Gene Polymorphism in Neutralization-Resistant SIVsmE543-3 Infection. Viruses 2021;13:1181. [PMID: 34205728 DOI: 10.3390/v13061181] [Reference Citation Analysis]
5 Oli AN, Obialor WO, Ifeanyichukwu MO, Odimegwu DC, Okoyeh JN, Emechebe GO, Adejumo SA, Ibeanu GC. Immunoinformatics and Vaccine Development: An Overview. Immunotargets Ther 2020;9:13-30. [PMID: 32161726 DOI: 10.2147/ITT.S241064] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
6 Soni D, Van Haren SD, Idoko OT, Evans JT, Diray-Arce J, Dowling DJ, Levy O. Towards Precision Vaccines: Lessons From the Second International Precision Vaccines Conference. Front Immunol 2020;11:590373. [PMID: 33178222 DOI: 10.3389/fimmu.2020.590373] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
7 Celis-Giraldo CT, López-Abán J, Muro A, Patarroyo MA, Manzano-Román R. Nanovaccines against Animal Pathogens: The Latest Findings. Vaccines (Basel) 2021;9:988. [PMID: 34579225 DOI: 10.3390/vaccines9090988] [Reference Citation Analysis]
8 Van Tilbeurgh M, Lemdani K, Beignon AS, Chapon C, Tchitchek N, Cheraitia L, Marcos Lopez E, Pascal Q, Le Grand R, Maisonnasse P, Manet C. Predictive Markers of Immunogenicity and Efficacy for Human Vaccines. Vaccines (Basel) 2021;9:579. [PMID: 34205932 DOI: 10.3390/vaccines9060579] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Diallo D, Santal C, Lagrée M, Martinot A, Dubos F. Vaccination coverage of children with chronic diseases is inadequate especially for specifically recommended vaccines. Acta Paediatr 2020;109:2677-84. [PMID: 32239549 DOI: 10.1111/apa.15275] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
10 Luetscher RND, McKitrick TR, Gao C, Mehta AY, McQuillan AM, Kardish R, Boligan KF, Song X, Lu L, Heimburg-Molinaro J, von Gunten S, Alter G, Cummings RD. Unique repertoire of anti-carbohydrate antibodies in individual human serum. Sci Rep 2020;10:15436. [PMID: 32963315 DOI: 10.1038/s41598-020-71967-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
11 Martinón-Torres F, Bertrand-Gerentes I, Oster P. A novel vaccine to prevent meningococcal disease beyond the first year of life: an early review of MenACYW-TT. Expert Rev Vaccines 2021;:1-24. [PMID: 34365870 DOI: 10.1080/14760584.2021.1964962] [Reference Citation Analysis]
12 Wagner A, Weinberger B. Vaccines to Prevent Infectious Diseases in the Older Population: Immunological Challenges and Future Perspectives. Front Immunol 2020;11:717. [PMID: 32391017 DOI: 10.3389/fimmu.2020.00717] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
13 Russo G, Reche P, Pennisi M, Pappalardo F. The combination of artificial intelligence and systems biology for intelligent vaccine design. Expert Opin Drug Discov 2020;15:1267-81. [PMID: 32662677 DOI: 10.1080/17460441.2020.1791076] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
14 Doubovetzky M, Ataman-Önal Y, Chousterman B, Feroldi E, Garçon N, Grillet MH, Kramer D, Laurent S, Lewis DJM, Luna E, Manigold T, Syntin P, Burdin N, Fraisse L, Jackson N. Safety biomarkers for development of vaccines and biologics: Report from the safety biomarkers symposium held on November 28-29, 2017, Marcy l'Etoile, France. Vaccine 2020;38:8055-63. [PMID: 33187767 DOI: 10.1016/j.vaccine.2020.10.015] [Reference Citation Analysis]